439. Polygenic stratification reveals differential response to V1b antagonism in pre-exposed patients with major depressive disorder: a post-hoc analysis of the phase 2 OLIVE trial

D Gehrlach, L Arvastson, C zu Eulenburg, B Müller-Myhsok, C Strote, H Eriksson · 2026

Read 439. Polygenic stratification reveals differential response to V1b antagonism in pre-exposed patients with major depressive disorder: a post-hoc analysis of the phase 2 OLIVE trial by D Gehrlach, L Arvastson, C zu Eulenburg, B Müller-Myhsok, C Strote, H Eriksson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13556810.txt.

Description

A gene-based score may predict who gains from a new depression drug, and a 2026 conference abstract by D Gehrlach and co-authors reports a second look at a finished trial. The drug, BH-200, blocks a receptor for vasopressin, a hormone tied to the body's stress system.

The original phase two trial, called OLIVE, tested the drug against placebo in adults with major depression. This later analysis focused on patients who had already failed at least one proper course of antidepressant in their current episode, a group close to treatment-resistant illness. A prebuilt score that combines many small gene effects was applied to that group. The aim was to test whether stress-system biology, read through genes, forecasts who responds to the drug.

Catalog record

CREATORD Gehrlach, L Arvastson, C zu Eulenburg, B Müller-Myhsok, C Strote, H Eriksson
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE4 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13556810

Browse the full library · About the Tower of Babel